Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 596.5% in February

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 11,249 shares, a growth of 596.5% from the January 29th total of 1,615 shares. Based on an average daily volume of 11,160 shares, the short-interest ratio is presently 1.0 days. Approximately 0.2% of the shares of the stock are sold short. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 11,160 shares, the short-interest ratio is presently 1.0 days.

Alterity Therapeutics Stock Performance

Shares of Alterity Therapeutics stock opened at $3.43 on Thursday. The business has a 50 day moving average price of $3.30 and a 200 day moving average price of $3.94. Alterity Therapeutics has a 1 year low of $2.52 and a 1 year high of $7.00.

Institutional Trading of Alterity Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Twin Lakes Capital Management LLC boosted its stake in shares of Alterity Therapeutics by 2,250.3% during the 3rd quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock worth $524,000 after purchasing an additional 133,333 shares during the last quarter. Greenleaf Trust lifted its stake in shares of Alterity Therapeutics by 88.2% during the third quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock valued at $120,000 after buying an additional 15,000 shares during the period. HB Wealth Management LLC acquired a new stake in Alterity Therapeutics during the third quarter worth approximately $220,000. Finally, Citadel Advisors LLC purchased a new stake in Alterity Therapeutics in the 3rd quarter worth approximately $83,000. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Wall Street Analyst Weigh In

ATHE has been the subject of a number of research reports. Canaccord Genuity Group began coverage on shares of Alterity Therapeutics in a research report on Wednesday, December 17th. They set a “speculative buy” rating for the company. Zacks Research raised Alterity Therapeutics to a “hold” rating in a report on Thursday, February 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold”.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.